THIS CONTENT IS BROUGHT TO YOU BY University of Oslo - read more

Professor Jukka Corander and his colleagues have made an important breakthrough in our understanding of how the use of antibiotics can result in more dangerous and more resistant bacteria.

Some antibiotics result in more multi-resistant and pathogenic E.coli

There is a clear correlation between the use of a particular type of antibiotic and the increased prevalence of a multi-resistant E. coli clone.

Published

After analysing 5,000 E. coli infections in Norway and UK during the period 2001-2017, the results leave no room for doubt.

In 2005, researchers showed for the very first time that the use of various antibiotics coincided with the occurrence of serious bacterial infections that were resistant to the same antibiotics. 

The report incorporated data from 26 European countries over a period of 6 years. It attracted a lot of attention because it presented the hypothesis that use of antibiotics drives an increased prevalence of antibiotic-resistant bacteria in the population.

“Now, for the first time, we have been able to verify this hypothesis for one type of antibiotic often used to combat E. coli infections,” Professor Jukka Corander says. He has led the new study.

Antibiotic resistance

Antibiotic resistance means that bacteria can continue to live and reproduce even when exposed to antibiotics. Some bacteria are naturally resistant to certain antibiotics. Both these and other bacteria can develop resistance to antibiotics they are exposed to.

Bacteria that are resistant to two or more antibiotics are called multi-resistant.

Typically, resistant bacteria do not cause more illness than non-resistant, sensitive bacteria. However, infections caused by resistant bacteria are more challenging to treat than other infections. 

(Source: Norwegian Institute of Public Health)

New and better technology

Technological developments, combined with data from two world-leading, national surveillance systems that monitor resistance in microbes, have provided researchers  with the opportunity to carry out big-data analyses in order to investigate the causal relationship between the use of antibiotics and the occurrence of antibiotic resistance.

This time, the researchers generated two parallel sets of data derived from cases of blood poisoning with E. coli bacteria occurring over almost two decades. One set from England during the period 2001-2017 and one from Norway from 2002-2017.

“By comparing the results of the DNA analyses with the frequency of antibiotic use in the two countries, we were able to determine which types of antibiotics are particularly important for the growth of certain E. coli strains that are resistant to antibiotics,” Corander says.

Greater occurrence of infections in England

With the help of extensive data simulations, the researchers were able to investigate how different levels of the use of the antibiotic cephalosporin are related to how prevalent a bacterial strain is in the population.

“Our conclusion is that a more intensive use of the antibiotic cephalosporin in England than in Norway has resulted in a higher occurrence of infections caused by the multi-resistant E. coli strain ST131-C2 in British society,” Corander says.

Recommends national surveillance systems

The study shows how important national surveillance systems are for combatting antibiotic resistance. 

With the help of analyses of representative data drawn from a number of years, it is possible to draw clear conclusions about which factors have a bearing on the development of antibiotic resistance.

References:

Goossens et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study, The Lancet, vol. 365, 2005. DOI: 10.1016/S0140-6736(05)17907-0

Pöntinen et al. Β-Lactam Antibiotic Use Modulates Multi-Drug Resistant Clone Success in Escherichia Coli Populations: A Longitudinal Multi-Country Genomic Cohort StudySSRN, 2023. DOI: 10.2139/ssrn.4364886

———

Read the Norwegian version of this article on forskning.no

Collaboration of researchers from many countries

The study included researchers from the University of Oslo, UiT the Arctic University of Norway; Turku University Hospital Finland, Ninewells Hospital and Medical School in Scotland, the University Hospital of North Norway, Imperial College London, the University of Birmingham, and the University of Cambridge.

The research was funded by the Norwegian Trond Mohn Foundation via the AMR BATTALION project, Marie Sklodowska-Curie Actions and the European Research Council (ERC). The genome sequencing was carried out at the Wellcome Sanger Institute in Great Britain.

Powered by Labrador CMS